Bridge Biotherapeutics Inc (288330 KQ) stock market data APIs
₩3720
-280(-7%)
as of January 22, 2025
Bridge Biotherapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade. The company was founded in 2015 and is headquartered in Seongnam, Korea.
Prev. Close
4000
Open
3720
Volume
1 354 K
High
4180
Low
3705
52 wk Range
1451.3002-6100
Market Cap
186 876 M
Shares Outstanding
46 314 K
Revenue
-340
EPS
-105.0104
Beta
0.91
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bridge Biotherapeutics Inc data using free add-ons & libraries
Get Bridge Biotherapeutics Inc Fundamental Data
Bridge Biotherapeutics Inc Fundamental data includes:
- Net Revenue: -340
- EBITDA: -29 007 851 520
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-09-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bridge Biotherapeutics Inc News
New
Bridge Biotherapeutics Joins PROLIFIC, the Prognostic Lung Fibrosis Consortium
Bridge to join as an industry member to advance the science of early detection and speed development of novel treatments SEONGNAM, South Korea and CAMBRIDGE, Mass., July 11, 2023 /PRNewswire/ -- Brid...
Bridge Biotherapeutics to Present at the 2023 BIO International Convention
SEONGNAM, South Korea and CAMBRIDGE, Mass., May 29, 2023 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs f...
Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207, a 4th generation EGFR TKI
The company has been notified by the FDA that the Phase 1/2 clinical trial may proceed The latest preclinical data explored the antitumor efficacy and the intracranial activity of BBT-207 SEONGNAM, S...
Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting
New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candidate Bridge submitted an IND application to the U.S. Food and Drug Administration in March, and expects to...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
